HC Wainwright Predicts Upstream Bio Q2 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – Analysts at HC Wainwright issued their Q2 2026 earnings estimates for shares of Upstream Bio in a research note issued on Wednesday, June 3rd. HC Wainwright analyst M. Caufield forecasts that the company will post earnings per share of ($0.76) for the quarter. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Upstream Bio’s Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($3.09) EPS, FY2028 earnings at ($2.92) EPS, FY2029 earnings at ($3.35) EPS and FY2030 earnings at ($3.42) EPS.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). The company had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $1.03 million. Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%.

UPB has been the subject of a number of other research reports. Mizuho cut their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Weiss Ratings cut shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Evercore cut shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective on the stock. in a research note on Friday, March 27th. Finally, Wall Street Zen cut shares of Upstream Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Upstream Bio has a consensus rating of “Moderate Buy” and a consensus price target of $38.20.

Upstream Bio Stock Down 2.6%

Shares of UPB opened at $7.43 on Friday. The company has a 50-day simple moving average of $9.10 and a 200-day simple moving average of $17.57. The company has a market capitalization of $404.34 million, a PE ratio of -2.55 and a beta of 1.10. Upstream Bio has a 52-week low of $7.18 and a 52-week high of $33.68.

Institutional Investors Weigh In On Upstream Bio

A number of large investors have recently added to or reduced their stakes in UPB. Norges Bank acquired a new stake in Upstream Bio in the 4th quarter valued at about $78,264,000. UBS Group AG grew its stake in Upstream Bio by 563.4% in the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock valued at $49,039,000 after acquiring an additional 1,533,972 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Upstream Bio in the 4th quarter valued at about $41,423,000. Y Intercept Hong Kong Ltd boosted its stake in shares of Upstream Bio by 2,049.2% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,000,631 shares of the company’s stock worth $9,006,000 after purchasing an additional 954,072 shares during the last quarter. Finally, SEB Asset Management AB acquired a new stake in shares of Upstream Bio during the 1st quarter worth about $7,906,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.